Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells

European Journal of Pharmacology

Volumn 347, Issue 1, 1998, Pages 87-94

  Kawai, Shinichi ^a   Nishida, Shinichi ^a   Kato, Miyako ^a   Furumaya, Yasuko ^a   Okamoto, Renzo ^b   Koshino, Tomihisa ^b   Mizushima, Yutaka ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Cyclooxygenase 1; Cyclooxygenase 2; Nonsteroidal anti inflammatory drug; Platelet; Synovial cell

Indexed keywords

ACETYLSALICYLIC ACID; DICLOFENAC; ETODOLAC; IBUPROFEN; INDOMETACIN; LOXOPROFEN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PROSTAGLANDIN SYNTHASE INHIBITOR; ZALTOPROFEN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SPECIFICITY; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SYNOVIOCYTE; THROMBOCYTE;

EID: 0032540212     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00078-8     Document Type: Article

References (32)

1. Anderson G.D., Hauser S.D., McGarity K.L., Bremer M.E., Isakson P.C., Gregory S.A. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J. Clin. Invest. 97:1996;2672-2679.
2. Appleton I., Tomlinson A., Willoughby D.A. Inducible cyclooxygenase (COX-2): a safer therapeutic target? Br. J. Rheumatol. 33:1994;410-412.
3. Arend W.P., Dayer J.M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum. 38:1995;151-160.
4. Brideau C., Kargman S., Liu S., Dallob A.L., Ehrich E.W., Rodger I.W., Chan C.-C. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm. Res. 45:1996;68-74.
5. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol chloroform extraction. Anal. Biochem. 162:1987;156-159.
6. Crofford L.J., Wilder R.L., Ristimaki A.P., Sano H., Remmers E.F., Epps H.R., Hla T. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1β, phorbolester, and corticosteroids. J. Clin. Invest. 93:1994;1095-1101.
7. Dayer J.-M., Krane S.M., Russell G.G., Robinson D.R. Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells. Proc. Natl. Acad. Sci. USA. 73:1976;945-949.
8. Emery P. Clinical implications of selective cyclooxygenase-2 inhibition. Scand. J. Rheumatol. 25:1996;23-28.
9. Flower R.J., Gryglewski R., Herbaczynska-Cedro K., Vane J.R. Effects of anti-inflammatory drugs on prostaglandin biosynthesis. Nature. 238:1972;104-106.
10. Futaki N., Yoshikawa K., Hamasaka Y., Arai I., Higuchi S., Iizuka H., Otomo S. NS-398, a novel anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen. Pharmacol. 24:1993;105-110.
11. Futaki N., Takahashi S., Yokoyama M., Arai I., Higuchi S., Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins. 47:1994;55-59.
12. Glaser K., Sung M.-L., O'Neill K., Belfast M., Hartman D., Carlson R., Kreft A., Kubrak D., Hsiao C.-L., Weichman B. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) vs. human PGHS-1. Eur. J. Pharmacol. 281:1995;107-111.
13. Grossman C.J., Wiseman J., Lucas F.S., Trevethick M.A., Birch P.J. Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDS and Cox inhibitors. Inflamm. Res. 44:1995;253-257.
14. Hayllar J., Bjarnason I. NSAIDs, Cox-2 inhibitors, and the gut. Lancet. 346:1995;521-522. comment.
15. Henry D., Lim L.L.-Y., Rodriguez L.A.G., Gutthann S.P., Carson J.L., Griffin M., Savage R., Logan R., Moride Y., Hawkey C., Hill S., Fries J.T. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br. Med. J. 312:1996;1563-1566.
16. 2 biosynthesis, active oxygen generation and bradykinin formation. Prostaglandins Leukotrienes Essent. Fatty Acids. 51:1994;457-462.
17. Kujubu D.A., Fletcher B.S., Varnum B.C., Lim R.W., Herschman H.R. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. 266:1991;12866-12872.
18. Laine L., Sloane R., Ferretti M., Cominelli F. A randomized, double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest. Endosc. 42:1995;428-433.
19. Laneuville O., Breuer D.K., Dewitt D.L., Hla T., Funk C.D., Smith W.L. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther. 271:1994;927-934.
20. Lanza F., Rack M.F., Lynn M., Wolf J., Sanda M. An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa. J. Rheumatol. 14:1987;338-341.
21. Masferrer J.L., Zweifel B.S., Manning P.T., Hauser S.D., Leahy K.M., Smith W.G., Isakson P.C., Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. USA. 91:1994;3228-3232.
22. Minkes M., Stanford N., Chi M.M.-Y., Roth G.J., Raz A., Needleman P., Majerus P.W. Cyclic adenosine 3′,5′-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions. J. Clin. Invest. 59:1977;449-454.
23. Mitchell J.A., Akarasereenont P., Thiemermann C., Flower R.J., Vane J.R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA. 90:1994;11693-11697.
24. Morita I., Schindler M., Regier M.K., Otto J.C., Hori T., DeWitt D.L., Smith W.L. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J. Biol. Chem. 270:1995;10902-10908.
25. O'Neill G.P., Ford-Hutchinson A.W. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 330:1993;156-160.
26. Riendeau D., Percival M.D., Boyce S., Brideau C., Charleson S., Cromlish W., Ethier D., Evans J., Falgueyret J.-P., Ford-Hutchinson A.W., Gordon R., Greig G., Gresser M., Guay J., Kargman S., Leger S., Mancini J.A., O'Neill G., Ouellet M., Rodger I.W., Therien M., Wang Z., Webb J.K., Wong E., Xu L., Young R.N., Zamboni R., Prasit P., Chan C.-C. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br. J. Pharmacol. 121:1997;105-117.
27. Sano H., Hla T., Maier J.A.M., Crofford L.J., Case J.P., Maciag T., Wilder R.L. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J. Clin. Invest. 89:1992;97-108.
28. Singh, G., Terry, R., Ramey, D., Halpern, J., Brown, W.B., 1997. Comparative GI toxicity of NSAIDs. XIXth ILAR Congress of Rheumatology, p. 159.
29. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231:1971;232-235.
30. Vane J.R., Botting R.M. Mechanism of action of anti-inflammatory drugs. Scand. J. Rheumatol. 25:1996;9-21.
31. Xie W., Chipman J.G., Robertson D.L., Erikson R.L., Simmons D.L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. USA. 88:1991;2692-2696.
32. 2 production following its intracellular conversion into cyclooxygenase inhibitors. Eur. J. Pharmacol. 329:1997;181-187.